Potential Role of CHI3L1+ Astrocytes in Progression in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 29, 2020
- Accepted in final form December 21, 2020
- First Published March 3, 2021.
Author Disclosures
- Laura Cubas-Núñez, PhD*,
- Sara Gil-Perotín, MD, PhD*,
- Jéssica Castillo-Villalba, BSc,
- Verónica López, BSc,
- Luis Solís Tarazona, MD,
- Raquel Gasqué-Rubio, BSc,
- Sara Carratalá-Boscá, MA,
- Carmen Alcalá-Vicente, MD, PhD,
- Francisco Pérez-Miralles, MD, PhD,
- Hans Lassmann, MD, PhD and
- Bonaventura Casanova, MD, PhD
- Laura Cubas-Núñez, PhD*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sara Gil-Perotín, MD, PhD*,
None
NONE
(1) Roche, speaker honoraria(2) Biogen, speaker honoraria(3) Sanofi genzyme, travel to educational meeting
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jéssica Castillo-Villalba, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Verónica López, BSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Collaboration grant. Education Ministry, 1, 1.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Luis Solís Tarazona, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Raquel Gasqué-Rubio, BSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sara Carratalá-Boscá, MA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Carmen Alcalá-Vicente, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Francisco Pérez-Miralles, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hans Lassmann, MD, PhD and
MEDDAY; Advisory board regarding neurodegeneration in MS.
NONE
I have received speaker and travel honoraria for several scientific meetings from Biogen Idec, Novartis, Roche and Teva.
I am member of the Editorial Board of several Journals in the fields of Neurology and Neuroscience.
NONE
NONE
NONE
I have served as a consultant for Medday and Roche.
NONE
NONE
NONE
NONE
Austrian Science Fund, Projects P27744, I 2114;principal investigator; 2014-2017 European Union PITN.GA-316722; Subproject; This funding is not directly related to the respective article
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bonaventura Casanova, MD, PhD
Roche Biogen-Idec Cenzyme TEVA Novartis Merck-Serono
NONE
NONE
NONE
NONE
NONE
NONE
Roche Biogen-Idec Genzyme TEVA Novartis Merck-Serono Gelcene-BMS
NONE
NONE
NONE
Biogen-Idec Genzyme TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimmunology Unit (L.C.-N., S.G.-P., J.C.-V., V.L., R.G., S.C., C.A., F.P.-M., B.C.), Polytechnic and University Hospital La Fe; Neurology Department (L.S.T.), University Hospital Dr Peset, Valencia, Spain; and Department of Neuroimmunology (H.L.), Center for Brain Research, Vienna, Austria.
- Correspondence
Dr. Gil-Perotín sara.garcia{at}uv.es
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Research Article
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple SclerosisPietro Maggi, Jens Kuhle, Sabine Schädelin et al.Neurology, June 04, 2021 -
Article
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated diseaseHyunjin Kim, Eun-Jae Lee, Seungmi Kim et al.Neurology: Neuroimmunology & Neuroinflammation, March 17, 2020 -
Article
Lesion activity and chronic demyelination are the major determinants of brain atrophy in MSChenyu Wang, Michael H. Barnett, Con Yiannikas et al.Neurology: Neuroimmunology & Neuroinflammation, July 16, 2019 -
Articles
Astrocytic damage is far more severe than demyelination in NMOA clinical CSF biomarker studyR. Takano, T. Misu, T. Takahashi et al.Neurology, July 19, 2010